Clinical utility of scintigraphy and SPECT/CT with 99m Tc-Tectrotyd in patients with neuroendocrine tumors
https://doi.org/10.33667/2078-5631-2020-20-42-45
Abstract
This article describes a new affordable diagnostic method of neuroendocrine tumors, shows the basic information on it’s conduction and interpretation of the results. Scintigraphy of neuroendocrine tumors with 99mTc-Tectro-tyd is a new alternative and more affordable diagnostic method that allows you to determine tumor receptor status, assess the prevalence of the tumor process and plan therapy. This study may also be the first step in planning radionuclide therapy for patients with neuroendocrine tumors. Also there is a short review on teranostics.
About the Authors
S. M. Kaspshik
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
M. B. Dolgushin
National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian Medical Academy of Post-Graduate Education
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Artamonova
National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian National Research Medical University n.a. N.I. Pirogov; Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Markovich
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
A. D. Ryzhkov
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
G. S. Emelyanova
Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov
Russian Federation
Moscow
Russian Federation
Moscow
M. E. Bilik
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology. 2004; 80: 394-424.
2. Kwekkeboom DJ, Krenning EP, Lebtahi R, Kommi-noth P, Kos-Kudta B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009; 90: 220-6.
3. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 20N; 30 (Suppl 1): 3-7.
4. Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract: A decade of experience at the princess margaret hospital. Am J Clin Oncol. 2008; 31: 64-70.
5. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995; 13: 2094-103.
6. Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59: 793-799.
7. Srirajaskanthan R, Kayani I, Quigley AM et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DT-PA-octreotidescintigraphy. J NuclMed2010;51:875-882.
8. Emilio Bombardieri, Valentina Ambrosini, Cumali Aktol-un, Richard P. Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio, Lorenzo Maffioli, Luc Mortemans, Wim Oyen, Giovanna Pepe, Arturo Chiti111 In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.
9. Babak Fallahi, Reyhaneh Manafi-Farid, Mohammad Eftekhari, Armaghan Fard-Esfahani, Alireza Emami-Ar-dekani, Parham Geramifar, Mehdi Akhlaghi, Amir Pejman HashemiTaheri, andDavood Beiki. Diagnostic Efficiency of 68Ga-DOTATATE PET/CT as Compared to 99mTc-Octreotide SPECT/CT and Conventional Morphologic Modalities in Neuroendocrine Tumors.
10. Haslerud T. SPECT-CT in neuroendocrine tumors. In: Clinical Application of SPECT-CT. Ahmadzadehfar H, Biersack HJ (eds). Springer-Verlag Heidelberg, New York, London 2014: 87-110.
11. Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJM. Nuclear Medicine Imaging of Neuroendocrine Tumors. In: Neuroendocrine tumors: A Multidisciplinary Approach. Papotti M, de Herder WW (eds). Front Horm Res. Basel, Karger2015; 44: 73-87.
12. Massimo Carlini Abdominal Neuroendocrine Tumors. DOI: 10.1007/978-88-470-3995-1.
Review
For citations:
Kaspshik S.M., Dolgushin M.B., Artamonova E.V., Markovich A.A., Ryzhkov A.D., Emelyanova G.S., Bilik M.E. Clinical utility of scintigraphy and SPECT/CT with 99m Tc-Tectrotyd in patients with neuroendocrine tumors. Medical alphabet. 2020;(20):42-45. (In Russ.) https://doi.org/10.33667/2078-5631-2020-20-42-45
Views:
1185
Email this article 